Tulane University School of Medicine
New Orleans, LA
Dr. Fonseca receives honoraria for consulting and speaking for Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Novo Nordisk, Sanofi-Aventis and Takeda. He has received research grants from Abbott, Eli Lilly, Endo Barrier, Novo Nordisk, Pan American Laboratories, Reata and Sanofi-Aventis.
|Program Name||Last Air Date||Hosts/Guests|
|New Horizons in Reducing Cardiovascular Risk in T2DM|
|Glycemic Control in T2DM: Patient-Centric Approaches Case||06/20/2020|
|Glycemic Control in T2DM: Opportunities and Challenges||06/21/2020|
|Choosing Between Insulin and Incretin Therapies||12/10/2010|
|Sodium-Glucose Transporters: A New Class of Diabetes Medications||10/01/2009|
You need to be logged in to save this episode to a playlist.